**PROGRAM**

**June 10 (1st day)**

08:30 OPENING REMARKS

● **Basic Science I. EGFR**
  
  **Chairpersons:** C. David James (USA), Motoo Nagane (Japan)

  08:45 BS 1 THE ROLE OF EGF RECEPTOR HETEROGENEITY IN DRIVING GLIOMA DEVELOPMENT  
  **Frank Furnari (USA)**

  09:00 BS 2 ABERRANT EGFR SIGNALING IN GLIOMA  
  **Oliver Boegler (USA)**

  09:15 BS 3 THE ROLE OF EGFR* SIGNALING PATHWAY FOR TUMOR MAINTENANCE AND ALTERNATIVE PATHWAYS IN GLIOBLASTOMA WHICH ENHANCE TUMOR GROWTH  
  **Akitake Mukasa (Japan)**

  09:30 BS 4 EGF RECEPTOR TYROSINE KINASE MEDIATES A NOVEL PATHWAY OF DRUG RESISTANCE IN MALIGNANT GLIOMAS VIA TYROSINE PHOSPHORYLATION AND FUNCTIONAL ACTIVATION OF GLUTATHIONE S-TRANSFERASE P1  
  **Tatsunori Okamura (USA)**

● **Basic Science II. Genetic and Expression Profile. Markers.**
  
  **Chairpersons:** Rolf Bjerkvig (Norway), Chifumi Kitanaka (Japan)

  09:55 BS 5 MULTIGENE PREDICTOR OF OUTCOME IN NEWLY DIAGNOSED GLIOBLASTOMA  
  **Kenneth D. Aldape (USA)**

  10:10 BS 6 USING GENE EXPRESSION PROFILING TO IDENTIFY A PROGNOSTIC MOLECULAR SPECTRUM IN GLIOMAS  
  **Mitsuki Shirahata (Japan)**

  10:20 BS 7 SPHINGOSINE-1-PHOSPHATE1 RECEPTOR REGULATES GLIOMA CELL PROLIFERATION AND CORRELATES WITH SURVIVAL OF PATIENTS WITH GLIOBLASTOMA  
  **Yuya Yoshida (Japan)**

  10:30 Coffee Break

● **Basic Science III. Invasion, Immunoresistance**
  
  **Chairpersons:** Frank Furnari (USA), Mitsutoshi Nakada (Japan)

  11:00 BS 8 *17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN DOWN- REGULATES HYALURONIC ACID-INDUCED GLIOMA INVASION BY BLOCKING MMP-9 SECRETION  
  **Seung H Lee (Korea)**

  11:06 BS 9 *INHIBITION OF GLIOMA INVASION BY SILENCING SPARC WITH SIRNA  
  **Takanori Ohnishi (Japan)**

  11:10 BS 11 THE GUANINE NUCLEOTIDE EXCHANGE FACTORS TRIO, ECT2, AND VAV3 MEDIATE THE INVASIVE BEHAVIOR OF GLIOBLASTOMA  
  **James Rutka (Canada)**

  11:20 BS 12 ELMO1 AND DOCK180, A BIPARTITE RAC1 GUANINE NUCLEOTIDE EXCHANGE FACTOR, PROMOTE HUMAN GLIOMA CELL INVASION  
  **Shiyuan Cheng (USA)**

  11:30 BS 13 A NOVEL SWITCH THAT LINKS PTEN TO THE CONTROL OF UBIQUITINATION, TRAIL SENSITIVITY, AND IMMUNORESISTANCE IN HUMAN GBM XENOGRAFT CELLS  
  **Russell O. Pieper (USA)**

*Posters are also displayed in the Poster Viewing Room.
Lunchtime Seminar: Temozolomide plus Interferon-beta for newly diagnosed GBM: INTEGRA study
(Sponsor: Toray Industries Co., Ltd.)

Chairperson: Soichiro Shibui (Japan)

12:00 LS A JAPANESE MULTICENTER CLINICAL TRIAL OF INTERFERON-B AND TEMOZOLOMIDE COMBINATION THERAPY FOR HIGH-GRADE GLIOMAS: FROM BENCH TO BEDSIDE
Atsushi Natsume (Japan), Toshihiko Wakabayashi (Japan)

New Therapeutic Approaches I

Chairpersons: Mitchel S. Berger (USA), Keisuke Ueki (Japan)

13:00 New 1 ENHANCING GLIOBLASTOMA CYTOTOXIC THERAPY THROUGH SMALL MOLECULE INHIBITION OF P53
C. David James (USA)

13:10 New 2 CYCLIN-DEPENDENT KINASE INHIBITOR FLAVOPIRIDOL ENHANCES CYTOTOXIC ACTION OF DNA-DAMAGING AGENTS ON HUMAN GLIOMA CELLS
Yuichi Hirose (Japan)

13:20 New 4 BORON NEUTRON CAPTURE THERAPY FOR NEWLY DIAGNOSED GLIOBLASTOMA
Shin-Ichi Miyatake (Japan)

13:30 New 5 MODULAR RECOMBINANT TRANSPORTERS: A FLEXIBLE PLATFORM FOR BRAIN TUMOR TARGETED RADIONUCLIDE THERAPY
Michael R. Zalutsky (USA)

13:40 New 6 NANO-PARTICLE MICELLE AS A DRUG DELIVERY SYSTEM FOR BRAIN TUMOR THERAPY
Yasushi Ino (Japan)

13:50 New 7 MR PARAMETERS AS NON-INVASIVE BIOMARKERS FOR PREDICTING SURVIVAL IN NEWLY DIAGNOSED PATIENTS WITH GLIOBLASTOMA MULTIFORME
Susan M. Chang (USA)

14:05 New 8 TREATMENT OF CNS RADIATION NECROSIS WITH BEVACIZUMAB, AN ANTI-VEGF ANTIBODY
Victor A. Levin (USA)

14:20 Stem 8 TUMOR-DERIVED MESENCHYMAL STEM CELLS IN HUMAN GLIOMAS
Frederick F. Lang (USA)

14:30 Coffee Break

Evening Symposium: Clinical Trials and Related Information
(Sponsor: Schering-Plough K.K.)

Chairpersons: Jan Buckner (USA), Tomokazu Aoki (Japan)

15:00 CT 10 A CLINICAL TRIAL FOR MALIGNANT GLOMAS BY JCOG-BRAIN TUMOR STUDY GROUP (JCOG 0305)
Soichiro Shibui (Japan)

15:12 CT 11 PROGNOSTIC VARIABLES IN RECURRENT HIGH-GRADE GLIOMA CLINICAL TRIALS: AN NCCTG AND NABTC JOINT ANALYSIS
Jan Buckner (USA)

15:32 CT 12 A PHASE I/II STUDY OF TEMOZOLOMIDE (TMZ) AND THE FARNESYLTRANSFERASE INHIBITOR, LONAFARNIB (SARAZARTM, SCH66336) IN RECURRENT, TMZ REFRACTORY GLIOBLASTOMA (GBM)
Mark R. Gilbert (USA)

15:44 CT 13 Metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma
Jong-Hyun Kim (Korea)
AN INTERGROUP PHASE III STUDY OF RADIATION THERAPY WITH OR WITHOUT TEMOZOLOMIDE FOR SYMPTOMATIC OR PROGRESSIVE LOW-GRADE GLIOMAS

David Schiff (USA)

THE EORTC BRAIN TUMOR GROUP: CURRENT DEVELOPMENTS

Martin J. van den Bent (Netherlands)

Garden Party

TREATMENT RESULT OF ANAPLASTIC OLIGODENDROGLIOMAS: PERSONAL EXPERIENCE

Young-Cho Koh (Korea)

BRAIN ATROPHY AND COGNITIVE FUNCTION FOLLOWING CHEMOTHERAPY TO OLIGODENDROGLIOMA

Keisuke Ueki (Japan)

AN ULTRASTRUCTURAL, IMMUNOHISTOCHEMICAL AND MORPHOMETRIC STUDY OF OLIGODENDROGLIOMAS WITH RESPECT TO CHROMOSOME 1P DELETION

Takashi Komori (Japan)

GENETIC PROFILE IN 1P- AND 19Q- DELETED OLIGODENDROGLIOMA WITH SHORT RELAPSE-FREE SURVIVAL

Jun-ichi Adachi (Japan)

DIFFERENTIAL ASSOCIATION OF CHROMOSOME 19 SNP VARIANTS WITH OLIGODENDROGLIOMA: A CASE-CASE COMPARISON

Robert B. Jenkins (USA)

AGE, PREOPERATIVE KPS AND MGMT PROMOTOR HYPERMETHYLATION DEFINE THE SURVIVAL OF THE PATIENTS WITH GLIOBLASTOMA

Yukihiko Sonoda (Japan)

MGMT PROMOTER METHYLATION STATUS IS A STRONG PREDICTIVE FACTOR FOR RESPONSE TO ACNU (NITROSOUREA) BASED RADIATION THERAPY IN NEWLY DIAGNOSED GLIOBLASTOMAS

Yoshitaka Narita (Japan)

PHASE II STUDY OF LOW DOSE ICE (IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE) FOR RECURRENT GLIOBLASTOMA

Tomokazu Aoki (Japan)

CENTRO SOME AMPLIFICATION INDUCED BY SURVIVIN SUPPRESSION ENHANCES BOTH CHROMOSOME INSTABILITY AND RADIOSENSITIVITY IN GLIOMA CELLS

Kaoru Kurisu (Japan)

THE WARBURG EFFECT AND TUMOR CELL SURVIVAL IN HUMAN GBM

Abhijit Guha (Canada)

GENETIC AND HYPOXIC MECHANISMS OF TISSUE FACTOR EXPRESSION AND THROMBOSIS IN GLIOBLASTOMA

Daniel J. Brat (USA)

GATA4 EXPRESSION IN THE NORMAL CNS AND ITS FREQUENT LOSS IN HUMAN GLIOMAS

Abhijit Guha (Canada)

THE EXPRESSION LEVEL OF S1P1 IS RELATED TO MIB-1 LABELING INDEX WHICH PREDICTS SURVIVAL IN GLIOBLASTOMA

Mitsutoshi Nakada (Japan)

ENHANCED TUMOR GROWTH ELICITED BY L- TYPE AMINO ACID TRANSPORTER 1 IN HUMAN MALIGNANT GLIOMA CELLS

Motoo Nagane (Japan)

THE RNA BINDING PROTEIN 76 CONTROLS GENE EXPRESSION IN GBM

Matthias Gromeier (USA)

*Posters are also displayed in the Poster Viewing Room.*
21:15  BS 21  EXPRESSION AND FUNCTIONAL SIGNIFICANCE OF INHIBITORS OF APOPTOSIS PROTEINS (IAPS) IN HUMAN GLIOMAS
Abhijit Guha  (Canada)

21:18  BS 22  DUAL BLOCKADE OF LIPID AND PROTEIN KINASES DRIVES APOPTOSIS IN GLIOMA
William A. Weiss  (USA)

21:21  BS 23  TARGETING THE TUMOR STROMA: A NOVEL THERAPEUTIC STRATEGY BASED ON SEPARATE ANALYSIS OF THE MALIGNANT AND STROMAL CELL COMPARTMENTS IN BRAIN TUMORS.
Jian Wang  (Norway)

21:24  BS 24  THE ROLE OF GLIAL CELLS IN BRAIN METASTASES OF TUMOR CELLS
Mami Noda  (Japan)

21:27  BS 27  FORMATION AND FUNCTIONAL MAPPING OF THE INTERACTION DOMAIN OF A PHYSICAL COMPLEX BETWEEN TGM2 AND GSTP1 THAT CONFERS CISPLATIN RESISTANCE IN MALIGNANT GLIOMA CELLS
Francis Ali-Osman  (USA)

June 11 (2nd day)

Cancer Stem Cell
Chairpersons: Manfred Westphal  (Germany), Hideyuki Saya  (Japan)

Stem 1  Cancelled  THE REAL AXIS OF EVIL: CANCER STEM CELLS IN TUMOR GROWTH, THERAPEUTIC RESISTANCE, AND ANGIOGENESIS
Anita B. Hjelmeland  (USA)

08:30  Stem 2  A HIERARCHY OF SELF-RENEWING TUMOR-INITIATING CELL TYPES IN GLIOBLASTOMA
Heidi S. Phillips  (USA)

08:45  Stem 3  CHARACTERIZATION AND TRANSFORMATION POTENTIAL OF SYNTHETIC ASTROCYTES DIFFERENTIATED FROM MURINE EMBRYONIC STEM CELLS
Abhijit Guha  (Canada)

09:00  Stem 4  CLINICAL AND BIOLOGICAL IMPLICATION OF CD133 POSITIVE AND NEGATIVE CELLS IN GLIOBLASTOMAS
Do-Hyun Nam  (Korea)

09:15  Stem 5  CD133 POSITIVE CELLS ARE STABLY ENTRAPPED IN SHORT-TERM CELL LINES DERIVED FROM MALIGNANT ASTROCYTOMA AND CONTRIBUTE TO CHEMORESISTANCE
John L. Darling  (UK)

09:30  Discussion

09:45  Coffee Break

10:15  Stem 6  CANDIDATE STEM CELL POPULATION FOR USE IN CNS TUMOR THERAPY
Catherine T. Flores  (UK)

10:30  Stem 7  HUMAN ADULT BRAIN CONTAINS NEURO-GLIAL PROGENITOR CELLS WHICH TARGET HUMAN GLIOMA XENOGRAFTS
Manfred Westphal  (Germany)

10:45  Stem 9  CEREBELLAR STEM CELLS LACKING RB AND P53 ACT AS TUMOUR INITIATING CELLS IN MEDULLOBLASTOMA PATHOGENESIS
Silvia Marino  (UK)

11:00  Stem 10  GLOBAL ANALYSES OF POLYCOMB MEDIATED TRANSCRIPTIONAL REPRESSION AND DNA METHYLATION TARGETS IN BRAIN TUMOR STEM CELLS
Atsushi Natsume  (Japan)

11:15  Discussion
12:00  
**Lunchtime Symposium: Primary CNS Lymphoma**  
(Sponsor: Chugai Pharmaceutical Co., Ltd.)  

**Chairpersons:** Brian Patrick O’Neill (USA), Takanori Ohnishi (Japan)

12:15 **PCNSL 1** PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN JAPAN: CHANGES IN CLINICAL FEATURES, TREATMENT AND PROGNOSIS DURING 1985-2004  
Yuta Shibamoto (Japan)

12:30 **PCNSL 2** RESPONSE AND SURVIVAL PATTERN IN PRIMARY CNS LYMPHOMA TREATED BY HIGH DOSE METHOTREXATE MONOCHIMOTHERAPY: ROLE OF STAT6 AS PROGNOSTIC DETERMINANT  
Yong-Kil Hong (Korea)

12:45 **PCNSL 3** IMMUNOCHEMOTHERAPY WITH RITUXIMAB IN CONJUNCTION WITH BLOOD-BRAIN BARRIER DISRUPTION AND AN ICE REGIMEN FOR RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS (PCNSL)  
Kazuhiko Mishima (Japan)

13:00 **PCNSL 4** *RACIAL/ETHNIC DIFFERENCES IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A SEER-BASED ESTIMATE OF INCIDENCE AND SURVIVAL RATES AMONG UNITED STATES BLACKS, WHITES, ASIAN/PACIFIC ISLANDERS AND AMERICAN INDIANS/ALASKAN NATIVES*  
Brian Patrick O’Neill (USA)

13:03 **PCNSL 5** *DEL (6)(Q22) AND BCL6 REARRANGEMENTS DETECTED BY INTERPHASE FLUORESCENCE IN-SITU HYBRIDIZATION (FISH) ARE UNFAVORABLE CYTOGENETIC ABNORMALITIES IN IMMUNOCOMPETENT (IC) PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)*  
Brian Patrick O’Neill (USA)

---

**Molecular Targeted Therapies**  
(Sponsor: Daiichi Sankyo Co., Ltd.)  

**Chairpersons:** Martin J. van den Bent (Netherlands), John L. Darling (UK)

13:45 **IL (Invited Lecture)** BIOMARKERS FOR PREDICTIVE AND PROGNOSTIC FACTORS  
Kazuto Nishio (Japan)

14:25 **MTT 1** PHASE II STUDY OF BEVACIZUMAB AND ERLOTINIB IN PATIENTS WITH RECURRENT GliobLASTOMA MULTIFORME  
David A. Reardon (USA)

14:45 **MTT 3** FEASIBILITY/TOLERABILITY RESULTS FROM A PHASE I/II STUDY OF TEmSIROLIMUS (CCI-779) AND SORAFENIB IN RECURRENT GliobLASTOMA: NORTH CENTRAL CANCER TREATMENT GROUP (NCCTG) N0572  
David Schiff (USA)

14:57 **MTT 4** PHASE I/II STUDY OF ERLOTINIB AND CCI-779 (TemSirolimus) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMAS (NABTC 04-02)  
Patrick Wen (USA)

15:30 Hakodate Sightseeing & Dinner

---

**June 12 (3rd day)**

**New Therapeutic Approaches II**  

**Chairpersons:** James Rutka (Canada), Tomoki Todo (Japan)

08:30 **New 17** *A CLINICAL TRIAL OF CATIONIC LIPOSOMES CONTAINING INTERFERON-BETA GENE FOR PATIENTS WITH MALIGNANT GLIOMA*  
Toshihiko Wakabayashi (Japan)

08:33 **New 18** *ANTI-EGF-R ANTIBODIES IN A HIGHLY INVASIVE XENOTRANSPLANT MODEL OF HUMAN GLIOMA*  
Manfred Westphal (Germany)

*Posters are also displayed in the Poster Viewing Room.*
08:36 New 19 *DICER-REGULATED MICRO RNAs 222 AND 339 PROMOTE IMMUNE-ESCAPE OF CANCER CELLS THROUGH DOWNREGULATION OF ICAM-1
Hideho Okada (USA)

08:39 New 20 *THE DNA DEMETHYLATING AGENT 5- Aza-2-DEOXYCYTIDINE INDUCES THE EXPRESSION OF CANCER-TESTIS ANTIGENS IN HUMAN GLIOMAS: EPIGENETIC TARGET FOR TUMOR IMMUNOTHERAPY
Atsushi Natsume (Japan)

08:42 New 22 *WT1 (WILMS TUMOR GENE) PEPTIDE VACCINATION FOR PATIENTS WITH RECURRENT GLIOBLASTOMA
Shuichi Izumoto (Japan)

08:45 New 23 *IDENTIFICATION OF AN HLA- A24-RESTRICTED T-CELL EPITOPE DERIVED FROM A GLIOMA-ASSOCIATED ANTIGEN, INTERLEUKIN 13 RECEPTOR ALPHA 2 CHAIN
Toshihiko Wakabayashi (Japan)

08:48 New 9 EXPERIMENTAL BRAIN TUMOR THERAPY USING ONCOLYTIC HSV-1 ARMED WITH INTERLEUKIN 12
Tomoki Todo (Japan)

08:58 New 11 DUAL-SPECIFIC IMMUNOTOXIN, D2C7 (scdsFv)-PE38KDEL, FOR BRAIN TUMOR TREATMENT
Chien-Tsun Kuan (USA)

09:08 New 12 RECOMBINANT ANTIBODY-BASED MOLECULAR THERAPEUTICS FOR BRAIN TUMOR IMMUNOTHERAPY
Kenji Wakiya (Japan)

09:18 New 13 INDUCTION OF IMMUNOLOGIC AND CLINICAL RESPONSES WITH EGFRvIII-TARGETED VACCINE (CDX-110) WITH CYCLES OF TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED EGFRvIII POSITIVE GBM
Gary E. Archer (USA)

09:28 New 14 TYPE-1 DENDRITIC CELL (DC) VACCINES IN COMBINATION WITH POLY-ICLC IN PARTICIPANTS WITH RECURRENT MALIGNANT GLIOMA
Hideho Okada (USA)

09:38 New 15 EFFICACY OF A RNA-PULSED DENDRITIC CELL VACCINES TARGETING CYTOMEGALOVIRUS ANTIGENS IN NEWLY-DIAGNOSED GBM
Duane A. Mitchell (USA)

09:48 New 16 REAL TIME MONITORING FOR CONVECTION-ENHANCED DELIVERY OF INTRATUMORAL CHEMOTHERAPY IS PREDICTIVE OF RESPONSE IN CANINE SPONTANEOUS GLIOMAS
Krystof S. Bankiewicz (USA)

10:00 Discussion
10:20 Coffee Break

●Pediatric Neuro-Oncology: CNSGCT

Chairpersons: Jonathan Finlay (USA), Masao Matsutani (Japan)

11:00 PNO 1 TREATMENT OF PRIMARY CNS GERMINOMATOUS GERM CELL TUMORS (GCT) WITH CHEMOTHERAPY PRIOR TO REDUCED DOSE VENTRICULAR FIELD IRRADIATION: THE CHILDREN’S HOSPITAL LOS ANGELES EXPERIENCE 2003-2007
Jonathan Finlay (USA)

11:20 PNO 2 LOW-DOSE RADIOTHERAPY AFTER INDUCTION CHEMOTHERAPY FOR INTRACRANIAL GERMINOMAS
Yutaka Sawamura (Japan)

11:40 PNO 3 TREATMENT RESULTS OF CONSECUTIVE 78 PATIENTS WITH INTRACRANIAL GERMINOMA IN A SINGLE INSTITUTE
Toshihiro Kumabe (Japan)

11:50 PNO 4 *CLINICAL EVALUATION OF PINEAL PARENCHYMAL TUMORS -HIROSHIMA UNIVERSITY HOSPITAL EXPERIENCES-
Kazuhiko Sugiyama (Japan)

11:53 PNO 6 *ENHANCED EXPRESSION OF DNA TOPOISOMERASE II GENES IN HUMAN MEDULLOBLASTOMA AND ITS POSSIBLE ASSOCIATION WITH ETOPOSIDE SENSITIVITY
Tadahisa Shono (Japan)

*Posters are also displayed in the Poster Viewing Room.
The 17th International Conference on Brain Tumor Research and Therapy

11:56 PNO 7 *IDENTIFICATION OF GENES AND PATHWAYS CRITICAL FOR TUMOR INITIATION, MAINTENANCE, AND PROGRESSION IN A MURINE MODEL OF LEPTOMENINGEAL METASTATIC MEDULLOBLASTOMA DRIVEN BY THE SLEEPING BEAUTY TRANSPSON
   Michael D. Taylor (Canada)

11:59 PNO 8 *IDENTIFICATION OF NT-3/TRK-C REGULATED PROTEINS IN MEDULLOBLASTOMA
   Irene Slavc (Austria)

12:02 PNO 10 *FACTORS AFFECTING OF MEDULLOBLASTOMAS IN CHILDREN
   Tai-T Wong (Taiwan)

12:10 LUNCH

● Medulloblastoma, PNET, AT/RT, Choroid plexus tumor
   Chairpersons: Mark W. Kieran (USA), Takaaki Yanagisawa (Japan)

13:30 PNO 11 ADULTS WITH MEDULLOBLASTOMA: TIME FOR A CHANGE IN MANAGEMENT
   Jonathan Finlay (USA)

13:50 PNO 12 TREATMENT OF ORTHOTOPIC MEDULLOBLASTOMAS WITH METRONOMIC TEMOZOLOMIDE AND 13-CIS-RETINOIC ACID
   Anat Erdreich-Epstein (USA)

14:00 PNO 13 MEDULLOBLASTOMA GROWTH ENHANCEMENT BY HGF/SF EXPRESSION IN CEREBELLAR NEURAL PROGENITOR CELLS IS SUPPRESSED BY SYSTEMIC ANTIBODY TREATMENT
   Daniel W. Fults (USA)

14:12 PNO 14 OTX2 is oncogenic and predicts decreased survival in medulloblastomas patients
   Sridharan Gururangan (USA)

14:24 PNO 16 RESULTS FROM A SINGLE-ARM, MULTI-INSTITUTIONAL PHASE II STUDY OF MULTI-AGENT INTRATHecal AND SYSTEMIC CHEMOTHERAPY WITH AGE- AND RISK-ADAPTED RADIATION THERAPY FOR CHILDREN WITH NEWLY DIAGNOSED CNS ATYpical TERAtOID/RHABDOID TUMOR
   Mark W. Kieran (USA)

   Johannes E. A. Wolff (USA)

15:00 Coffee Break

● Neurocognitive function and outcome
   Chairperson: Ryo Nishikawa (Japan)

15:30 OUT 1 LATE EFFECTS FOLLOW-UP OF HEAD START II SURVIVORS
   Stephen Sands (USA)

15:40 OUT 2 NEUROPSYCHOLOGICAL OUTCOME OF SURVIVORS OF PEDIATRIC MALIGNANT GLIOMA
   Stephen Sands (USA)

16:00 CLOSING REMARKS

18:30-21:00 FAREWELL DINNER

*Posters are also displayed in the Poster Viewing Room.